A biochemical signature of alcohol use that can't be faked or forgotten
For decades, the gap between what patients say about their drinking and what their bodies reveal has quietly shaped—and sometimes distorted—some of medicine's most consequential decisions. Researchers in Sydney have now developed a blood test measuring phosphatidylethanol, a compound the body produces only in the presence of alcohol, that detects consumption with 95% accuracy and remains traceable for up to five weeks. The finding arrives at a critical intersection of biochemistry and ethics: in the world of liver transplantation, where a second chance at life depends on honest reckoning with the first, science has found a way to ask the question that shame and fear so often leave unanswered.
- More than one-third of patients who denied drinking were contradicted by their own blood, exposing a silent crisis of underreporting in liver disease care.
- Traditional biomarkers and self-assessments have long left transplant teams navigating in the dark when making irreversible decisions about who receives a donor liver.
- The PEth test doesn't just detect alcohol—it distinguishes between heavy and very heavy consumption and holds its signal for up to five weeks, giving clinicians an unprecedented window into patient behavior.
- Transplant units at Sydney's Royal Prince Alfred Hospital are already implementing the test, signaling a shift from trust-based assessment toward biochemical accountability.
- Researchers believe widespread adoption could transform not only transplant eligibility decisions but also post-surgery relapse prevention strategies for patients with alcohol use disorder.
Doctors in liver clinics have long wrestled with a quiet but consequential problem: patients don't always tell the truth about how much they drink. Some minimize. Some fear judgment. Some may not fully remember. The result is treatment plans built on uncertain ground—and, in the worst cases, transplant decisions that unravel after surgery. Researchers at the Centenary Institute and Sydney Local Health District have now developed a tool designed to close that gap: a blood test measuring phosphatidylethanol, or PEth, that detects alcohol use with 95% accuracy, outperforming both standard biomarkers and patient self-reports.
PEth forms in the body only when alcohol is consumed—a biochemical signature that cannot be faked or hidden. In a study of 183 participants spanning alcohol-related liver disease, alcohol use disorder, and healthy controls, the test proved decisive. It could distinguish between heavy and very heavy drinking, and it remained detectable for up to five weeks, making it useful for tracking behavioral change over time. The most striking finding: more than one-third of patients who denied drinking showed PEth evidence of recent alcohol use—not necessarily from deception, but from shame, denial, or the quiet erosion of self-awareness that often accompanies addiction.
The stakes are especially high in transplant medicine. Clinical Professor Devanshi Seth described PEth as both highly sensitive and highly accurate for monitoring whether patients are genuinely changing their habits. Dr. Anastasia Volovets, a liver transplant specialist, noted that patients may underreport drinking out of fear of disqualification—making a chemistry-based assessment far more reliable than one built on memory or motivation alone.
The test is already being rolled out at Royal Prince Alfred Hospital's Liver Transplant Unit, with researchers anticipating broader adoption across liver clinics and transplant programs. A liver transplant represents a second chance at life—one that demands honesty about the very thing that may have ended the first. Now, for the first time, that honesty can be confirmed without asking for it.
Doctors have long faced a stubborn problem in liver clinics: patients don't always tell the truth about how much they drink. Some lie outright. Others minimize. Some genuinely don't remember. The consequences of this silence can be severe—a patient deemed safe for a liver transplant who then relapses, a treatment plan built on false assumptions, a second chance squandered. Now researchers at the Centenary Institute and Sydney Local Health District have found a way to see through the fog: a blood test that detects alcohol use with 95% accuracy, far outpacing both the standard biomarkers doctors have relied on and what patients report about themselves.
The test measures phosphatidylethanol, or PEth, a compound that forms in the body only when alcohol is consumed. It's a biochemical signature—impossible to fake, impossible to hide. In a study published in Alcohol, Clinical and Experimental Research, researchers tracked 183 people across three groups: those with alcohol-related liver disease, those with alcohol use disorder, and healthy controls. They asked participants about their drinking, then compared those self-reports against PEth levels and other established alcohol markers. The PEth test won decisively. It didn't just detect whether someone had been drinking; it could distinguish between heavy drinking (300 micrograms per liter) and very heavy drinking (600 micrograms per liter). More strikingly, it remained detectable for up to five weeks—longer than many competing tests—making it useful for tracking changes in behavior over time.
The most unsettling finding emerged in the details: more than one-third of patients who insisted they weren't drinking showed PEth evidence of recent alcohol use. These weren't necessarily people trying to deceive their doctors. Some may have been in denial. Others may have felt ashamed or feared judgment. Some may have simply forgotten a drink or two. But the gap between what they said and what their blood revealed was stark, and it matters enormously in the context of liver disease, which affects roughly one in three Australians and is growing faster than many other health conditions. While excessive drinking is a major driver, obesity, viral hepatitis, and autoimmune conditions also play significant roles.
For transplant teams, the implications are profound. Clinical Professor Devanshi Seth, the study's senior author, framed it plainly: PEth is both highly sensitive and highly accurate, making it ideal for monitoring whether patients are actually changing their drinking habits. Dr. Anastasia Volovets, a specialist on the liver transplant team at Sydney Local Health District, put it more directly: accurate alcohol detection is vital when deciding who gets a new liver. Patients being considered for transplant may underreport their drinking unintentionally or because they fear disqualification. A clearer picture—one drawn from blood chemistry rather than memory or motivation—allows doctors to make better decisions about who is ready, who needs more support, and how to prevent relapse after surgery.
The test is already being rolled out at the Royal Prince Alfred Hospital's Liver Transplant Unit, and researchers believe it could become standard practice across liver clinics and transplant programs. The stakes are high enough to justify it: a liver transplant is a second chance at life, and it requires honesty about the very thing that may have destroyed the first liver. Now doctors have a tool that doesn't depend on honesty. It depends on chemistry.
Citas Notables
PEth is a biochemical signature of alcohol use that can be detected for up to five weeks after drinking and is both highly sensitive and very accurate, making it ideal for monitoring changes in alcohol consumption behavior over time.— Clinical Professor Devanshi Seth, senior author
Accurate alcohol detection is vital in transplant settings because it allows doctors to support patients with alcohol use disorder and make the best decisions for transplant eligibility and post-transplant relapse prevention.— Dr. Anastasia Volovets, Liver Transplant Team specialist
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter so much whether patients are truthful about their drinking? Can't doctors just treat the liver disease itself?
Because alcohol use disorder is a disease too, and it doesn't stop at the liver. If someone gets a transplant but keeps drinking, the new liver fails just like the old one. You're giving them a second chance that gets wasted. So transplant teams need to know: is this person ready to stop, or are they still in denial about their drinking?
But the study found that a third of patients who said they weren't drinking actually were. That's a lot of people lying.
Not necessarily lying. Some are in denial. Some are ashamed. Some genuinely don't track their intake carefully. The point is that self-report is unreliable—not because people are dishonest, but because drinking and memory and shame all tangle together. This test cuts through that.
How long does PEth stay in the blood?
Up to five weeks. That's longer than most other markers, which is why it's useful for tracking patterns over time. You can see if someone's actually reducing their intake, not just whether they had a drink yesterday.
What happens now? Does every liver patient get tested?
It's being introduced at transplant units first, where the stakes are highest. But the researchers think it could become standard in liver clinics more broadly. The test exists. The evidence is clear. It's a matter of adoption.
Does knowing about the test change how patients behave?
That's the hope. If patients know their drinking will show up in blood work, they might be more honest with themselves and their doctors. And if doctors have accurate information, they can offer better support—not judgment, but real help.